株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

尋常性白斑 - 疫学予測 2028

Vitiligo - Epidemiology Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 524480
出版日 ページ情報 英文 92 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
尋常性白斑 - 疫学予測 2028 Vitiligo - Epidemiology Forecast - 2028
出版日: 2019年08月01日 ページ情報: 英文 92 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の尋常性白斑の有病者数は2017年に623万4,655人と推計されています。7カ国を比較すると、米国の有病者数が最も多くなっています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の尋常性白斑市場を調査し、市場の概要、タイプ別・年齢別・性別の有病数の推移と予測、疾病背景、国別の詳細動向などをまとめています。

目次

第1章 重要洞察

第2章 尋常性白斑:患者概要

  • 患者分布(実数値)
  • 患者分布(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • 尋常性白斑のタイプ
  • 原因
  • 症状
  • 病態生理
  • 遺伝学
  • 診断
    • 診断ガイドライン

第4章 疫学と患者人口

  • 主な調査結果
  • 人口と予測パラメータ
  • 主要7カ国の有病者数

第5章 米国における尋常性白斑の疫学

  • 仮定と根拠
  • 有病数
  • 有病数:性別
  • 診断数
  • 診断有病数:タイプ別
  • 有病数:年齢別

第6章 欧州5カ国における尋常性白斑の疫学

  • 仮定と根拠
  • ドイツ
    • 仮定と根拠
    • 有病数
    • 有病数:性別
    • 診断数
    • 診断有病数:タイプ別
    • 有病数:年齢別
  • フランス
    • 仮定と根拠
    • 有病数
    • 有病数:性別
    • 診断数
    • 診断有病数:タイプ別
    • 有病数:年齢別
  • イタリア
    • 仮定と根拠
    • 有病数
    • 有病数:性別
    • 診断数
    • 診断有病数:タイプ別
    • 有病数:年齢別
  • スペイン
    • 仮定と根拠
    • 有病数
    • 有病数:性別
    • 診断数
    • 診断有病数:タイプ別
    • 有病数:年齢別
  • 英国
    • 仮定と根拠
    • 有病数
    • 有病数:性別
    • 診断数
    • 診断有病数:タイプ別
    • 有病数:年齢別

第7章 日本における尋常性白斑の疫学

  • 仮定と根拠
  • 有病数
  • 有病数:性別
  • 診断数
  • 診断有病数:タイプ別
  • 有病数:年齢別

第8章 付録

  • 報告方法

第9章 出典

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1 Fitzpatrick skin types classification
  • Table 2 Levels of evidence (from Scottish Inter-Collegiate Guidelines Network)
  • Table 3 Grades of recommendation (from Scottish Inter-Collegiate Guidelines Network)
  • Table 4 Criteria for levels of evidence and grades of recommendation
  • Table 5 Total Prevalent Population of Vitiligo in 7MM (2017-2028)
  • Table 6 Prevalent Population of Vitiligo in the United States (2017-2028)
  • Table 7 Gender-Specific Prevalent Population of Vitiligo in the United States (2017-2028)
  • Table 8 Diagnosed cases of Vitiligo in the United States (2017-2028)
  • Table 9 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States (2017-2028)
  • Table 10 Age-Specific Prevalent cases of Vitiligo in the United States (2018)
  • Table 11 Prevalent Population of Vitiligo in Germany (2017-2028)
  • Table 12 Gender-Specific Prevalent Population of Vitiligo in Germany (2017-2028)
  • Table 13 Diagnosed cases of Vitiligo in Germany (2017-2028)
  • Table 14 Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany (2017-2028)
  • Table 15 Age-Specific Prevalent cases of Vitiligo in Germany (2018)
  • Table 16 Prevalent Population of Vitiligo in France (2017-2028)
  • Table 17 Gender-Specific Prevalent Population of Vitiligo in France (2017-2028)
  • Table 18 Diagnosed cases of Vitiligo in the France (2017-2028)
  • Table 19 Type-Specific Diagnosed Prevalent cases of Vitiligo in France (2017-2028)
  • Table 20 Age-Specific Prevalent cases of Vitiligo in France (2018)
  • Table 21 Prevalent Population of Vitiligo in Italy (2017-2028)
  • Table 22 Gender-Specific Prevalent Population of Vitiligo in Italy (2017-2028)
  • Table 23 Diagnosed cases of Vitiligo in Italy (2017-2028)
  • Table 24 Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy (2017-2028)
  • Table 25 Age-Specific Prevalent cases of Vitiligo in Italy (2018)
  • Table 26 Prevalent Population of Vitiligo in Spain (2017-2028)
  • Table 27 Gender-Specific Prevalent Population of Vitiligo in Spain (2017-2028)
  • Table 28 Diagnosed cases of Vitiligo in Spain (2017-2028)
  • Table 29 Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain (2017-2028)
  • Table 30 Age-Specific Prevalent cases of Vitiligo in Spain (2018)
  • Table 31 Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Table 32 Gender-Specific Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Table 33 Diagnosed cases of Vitiligo in the UK (2017-2028)
  • Table 34 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2017-2028)
  • Table 35 Age-Specific Prevalent cases of Vitiligo in the UK (2018)
  • Table 36 Prevalent Population of Vitiligo in Japan (2017-2028)
  • Table 37 Gender-Specific Prevalent Population of Vitiligo in Japan (2017-2028)
  • Table 38 Diagnosed cases of Vitiligo in Japan (2017-2028)
  • Table 39 Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan (2017-2028)
  • Table 40 Age-Specific Prevalent cases of Vitiligo in Japan (2018)

List of Figures

  • Figure 1 Types of Vitiligo
  • Figure 2 Type of Non-segmental Vitiligo
  • Figure 3 Symptoms of Vitiligo
  • Figure 4 Cellular and Humoral immune mechanisms of Vitiligo
  • Figure 5 Pathogenesis of Vitiligo
  • Figure 6 Identification of Vitiligo susceptibility genes
  • Figure 7 Total Prevalent Population of Vitiligo in the 7 MM (2017-2028)
  • Figure 8 Prevalent Population of Vitiligo in the United States (2017-2028)
  • Figure 9 Gender-Specific Prevalent Population of Vitiligo in the United States (2017-2028)
  • Figure 10 Diagnosed cases of Vitiligo in the United States (2017-2028)
  • Figure 11 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States (2017-2028)
  • Figure 12 Age-Specific Prevalent cases of Vitiligo in the United States (2018)
  • Figure 13 Prevalent Population of Vitiligo in Germany (2017-2028)
  • Figure 14 Gender-Specific Prevalent Population of Vitiligo in Germany (2017-2028)
  • Figure 15 Diagnosed cases of Vitiligo in Germany (2017-2028)
  • Figure 16 Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany (2017-2028)
  • Figure 17 Age-Specific Prevalent cases of Vitiligo in Germany (2018)
  • Figure 18 Prevalent Population of Vitiligo in France (2017-2028)
  • Figure 19 Gender-Specific Prevalent Population of Vitiligo in France (2017-2028)
  • Figure 20 Diagnosed cases of Vitiligo in France (2017-2028)
  • Figure 21 Type-Specific Diagnosed Prevalent cases of Vitiligo in France (2017-2028)
  • Figure 22 Age-Specific Prevalent cases of Vitiligo in France (2018)
  • Figure 23 Prevalent Population of Vitiligo in Italy (2017-2028)
  • Figure 24 Gender-Specific Prevalent Population of Vitiligo in Italy (2017-2028)
  • Figure 25 Diagnosed cases of Vitiligo in Italy (2017-2028)
  • Figure 26 Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy (2017-2028)
  • Figure 27 Age-Specific Prevalent cases of Vitiligo in Italy (2018)
  • Figure 28 Prevalent Population of Vitiligo in Spain (2017-2028)
  • Figure 29 Gender-Specific Prevalent Population of Vitiligo in Spain (2017-2028)
  • Figure 30 Diagnosed cases of Vitiligo in Spain (2017-2028)
  • Figure 31 Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain (2017-2028)
  • Figure 32 Age-Specific Prevalent cases of Vitiligo in Spain (2018)
  • Figure 33 Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Figure 34 Gender-Specific Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Figure 35 Diagnosed cases of Vitiligo in the UK (2017-2028)
  • Figure 36 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2017-2028)
  • Figure 37 Age-Specific Prevalent cases of Vitiligo in the UK (2018)
  • Figure 38 Prevalent Population of Vitiligo in Japan (2017-2028)
  • Figure 39 Gender-Specific Prevalent Population of Vitiligo in Japan (2017-2028)
  • Figure 40 Diagnosed cases of Vitiligo in Japan (2017-2028)
  • Figure 41 Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan (2017-2028)
  • Figure 42 Age-Specific Prevalent cases of Vitiligo in Japan (2018)
目次
Product Code: DIEI0066

DelveInsight's 'Vitiligo - Epidemiology Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology of Vitiligo in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Vitiligo - Disease Understanding

The American Vitiligo Research foundation defines Vitiligo as a condition in which the skin loses melanin, the pigment that determines the color of skin, hair, and eyes. If the cells that do not produce melanin die or no longer produce melanin, slowing growing white patches of irregular shapes appear on the skin. The typical lesions on the skin can be defined as milky white, non-scaly macules that are present with distinct margins. Vitiligo can also affect the mucous membranes, including tissues inside the mouth and nose. It can affect people of all skin types but is generally noticeable much in darker-skinned people.

Researchers have identified several forms of Vitiligo. Generalized Vitiligo (also called non-segmental Vitiligo), which is the most common form, involves loss of pigment (depigmentation) in patches of skin all over the body. Depigmentation typically occurs on the face, neck, and scalp, and around body openings such as the mouth and genitals. Sometimes pigment is lost in mucous membranes, such as the lips. Loss of pigmentation is also frequently seen in areas that tend to experience rubbing, impact, or other trauma, such as the hands, arms, and places where bones are close to the skin surface (bony prominences).

Another form called segmental Vitiligo (also known as unilateral or localised Vitiligo) is associated with smaller patches of depigmented skin that appear on one side of the body in a limited area; this occurs in about 10% of affected individuals. In segmental Vitiligo, the white patches only affect one area of the body. Segmental Vitiligo is less common than non-segmental Vitiligo, although it's more common in children.

The DelveInsight Vitiligo epidemiology report gives a thorough understanding of the Vitiligo by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

Vitiligo

The Vitiligo epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Vitiligo in 7MM, Total Diagnosed Prevalence of Vitiligo in 7MM, Gender-specific Prevalence of Vitiligo in 7MM, Age-specific Diagnosed Prevalence of Vitiligo in 7MM, and Type-specific Diagnosed Prevalence of Vitiligo in 7MM) scenario of Vitiligo in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent population of Vitiligo was found to be 6,234,655 in 7MM in the year 2017. Also suggests the United States showed the highest number of cases with Vitiligo, as compared to other 7MM countries.

Among the European countries, Germany has the highest prevalent population with 472,057 cases followed by the United Kingdom which has prevalent population of 290,965 in 2017. DelveInsight's epidemiology model suggests that overall, female population was found to be more prevalent than male population. Based on the type of Vitiligo, non-segmental Vitiligo was found to be more prevalent, across the 7MM countries.

Report Scope

  • The report covers a descriptive overview of the Vitiligo, explaining its causes, risk factors, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the epidemiology of Vitiligo in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in the 7MM countries with respect to the patient population.

Key strengths

  • 10 Year Forecast
  • 7MM countries
  • Total Patient Pool of Vitiligo
  • Type-specific Patient Pool of Vitiligo

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Type-specific cases of Vitiligo

Table of Contents

1. Key Insights

2. Vitiligo: Patient Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Vitiligo in 2017
  • 2.2. Patient Share (%) Distribution of Vitiligo in 2028

3. Disease Background and Overview: Vitiligo

  • 3.1. Introduction
  • 3.2. Types of Vitiligo
  • 3.3. Causes of Vitiligo
  • 3.4. Symptoms of Vitiligo
  • 3.5. Pathophysiology
  • 3.6. Genetics of Vitiligo
  • 3.7. Diagnosis
    • 3.7.1. Diagnostic Guidelines

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Prevalent Population of Vitiligo in 7MM

5. United States-Epidemiology of Vitiligo

  • 5.1. Assumptions and Rationale
  • 5.2. Prevalent Population of Vitiligo in the United States
  • 5.3. Gender-Specific Prevalent Population of Vitiligo in the United States
  • 5.4. Diagnosed Cases of Vitiligo in the United States
  • 5.5. Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States
  • 5.6. Age-Specific Prevalent cases of Vitiligo in the United States

6. EU-5 Epidemiology of Vitiligo

  • 6.1. Assumptions and Rationale
  • 6.2. Germany
    • 6.2.1. Prevalent Population of Vitiligo in Germany
    • 6.2.2. Gender-Specific Prevalent Population of Vitiligo in Germany
    • 6.2.3. Diagnosed Cases of Vitiligo in Germany
    • 6.2.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany
    • 6.2.5. Age-Specific Prevalent cases of Vitiligo in Germany
  • 6.3. France
    • 6.3.1. Prevalent Population of Vitiligo in France
    • 6.3.2. Gender-Specific Prevalent Population of Vitiligo in France
    • 6.3.3. Diagnosed Cases of Vitiligo in France
    • 6.3.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in France
    • 6.3.5. Age-Specific Prevalent cases of Vitiligo in France
  • 6.4. Italy
    • 6.4.1. Prevalent Population of Vitiligo in Italy
    • 6.4.2. Gender-Specific Prevalent Population of Vitiligo in Italy
    • 6.4.3. Diagnosed Cases of Vitiligo in Italy
    • 6.4.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy
    • 6.4.5. Age-Specific Prevalent cases of Vitiligo in Italy
  • 6.5. Spain
    • 6.5.1. Prevalent Population of Vitiligo in Spain
    • 6.5.2. Gender-Specific Prevalent Population of Vitiligo in Spain
    • 6.5.3. Diagnosed Cases of Vitiligo in Spain
    • 6.5.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain
    • 6.5.5. Age-Specific Prevalent cases of Vitiligo in Spain
  • 6.6. United Kingdom
    • 6.6.1. Prevalent Population of Vitiligo in the United Kingdom
    • 6.6.2. Gender-Specific Prevalent Population of Vitiligo in the United Kingdom
    • 6.6.3. Diagnosed Cases of Vitiligo in the United Kingdom
    • 6.6.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom
    • 6.6.5. Age-Specific Prevalent cases of Vitiligo in the United Kingdom

7. Japan-Epidemiology of Vitiligo

  • 7.1. Assumptions and Rationale
  • 7.2. Prevalent Population of Vitiligo in Japan
  • 7.3. Gender-Specific Prevalent Population of Vitiligo in Japan
  • 7.4. Diagnosed Cases of Vitiligo in Japan
  • 7.5. Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan
  • 7.6. Age-Specific Prevalent cases of Vitiligo in Japan

8. Appendix

  • 8.1. Report Methodology

9. Sources Used

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Back to Top